Tony Hunter, PhD
Director, The Salk Institute Cancer Center; American Cancer Society Professor of Molecular and Cell Biology, Renato Dulbecco Chair, The Salk Institute for Biological Studies; La Jolla, California
Following his seminal discovery that tyrosine residues in proteins are phosphorylated by specific kinases, Dr. Hunter has focused his research on dissecting the role that post-translational modification of proteins has in controlling cell growth and proliferation. His findings revolutionized molecular biology in identifying a third amino acid, in addition to serine and threonine, which is phosphorylated in the cell. The aberrant regulation of tyrosine kinases has been shown to be a critical hallmark of many cancer cells.
Dubbed the Kinase King, Dr. Hunter identified one of the critical switches required to initiate normal cell proliferation and showed that this tyrosine kinase switch is frequently permanently turned on in cancer cells. His work has led to the discovery and development of many effective drugs targeting aberrant kinase signaling in cancer cells. When not in the laboratory, he can be found either running the rapids in the Grand Canyon or camping in the desert.
2017 Sjöberg Prize 2007 Clifford Prize for Cancer Research2006 Pasarow Award in Cancer Research2006 Daniel Nathan’s Memorial Award2006 Elected Member, American Philosophical Society2005 Wolf Prize in Medicine2004 AACR - Kirk A. Landon Prize for Basic Cancer Research2004 Elected Member, Institute of Medicine2004 Louisa Gross Horwitz Prize2001 Keio Medical Science Prize1998 Elected Member, National Academy of Sciences, Washington, DC1994 Charles S. Mott Prize, General Motors Cancer Research Foundation1994 Gairdner Foundation International Award1992 Elected Fellow, American Academy of Arts and Sciences1987 Elected Fellow, Royal Society of London1969 PhD, University of Cambridge